Clinical Trial

Circulating Tumor DNA Response In Urothelial Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-12; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2025-12-02
Trial Details
NCT Number NCT07183319
Lead Sponsor University of Oklahoma
Collaborators: Natera, Inc.
Conditions Urothelial Carcinoma
Enrollment 30 participants
Start Date 2026-01-19
Primary Completion 2028-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-02